Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Metabolic syndrome in clinical practice..
Cardiol J. 21(2), 209.
(2014). Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors..
Curr Pharm Des. 20(40), 6215-9.
(2014). Peripheral artery disease in patients with type 2 diabetes..
J Diabetes Complications. 28(6), 912.
(2014). Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit..
Expert Rev Cardiovasc Ther. 12(3), 295-6.
(2014). Reaching hypertriglyceridemia goals..
Curr Med Res Opin. 30(3), 391-3.
(2014). Renal denervation: transition from pathophysiology to clinical practice..
Angiology. 65(9), 760-8.
(2014). The role of statins in the treatment of type 2 diabetes mellitus: an update..
Curr Pharm Des. 20(22), 3665-74.
(2014). Should we expand the concept of coronary heart disease equivalents?.
Curr Opin Cardiol. 29(4), 389-95.
(2014). Treating heart failure with preserved ejection fraction: statins could make the difference..
Angiology. 65(4), 328-9.
(2014). Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!.
Curr Med Res Opin. 30(12), 2425-8.
(2014). 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?.
Metabolism. 62(1), 21-33.
(2013). Alcohol consumption and the heart..
Int J Cardiol. 168(4), 4319.
(2013). Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients..
Curr Med Res Opin. 29(7), 791-2.
(2013). Cold temperature and cardiovascular mortality..
Circ J. 77(11), 2846.
(2013). Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease..
Expert Opin Ther Targets. 17(7), 861-2.
(2013). Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property"..
Dig Liver Dis. 45(1), 82-3.
(2013). Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review..
Curr Med Res Opin. 29(10), 1263-74.
(2013). The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study..
Curr Vasc Pharmacol. 11(5), 779-84.
(2013). Metabolic syndrome and arterial stiffness: the past, the present and the future..
J Cardiovasc Med (Hagerstown). 14(10), 687-9.
(2013). Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations..
Angiology. 64(8), 572-5.
(2013). Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention..
Circ J. 77(5), 1348.
(2013). Statins and nonalcoholic fatty liver disease: a bright future?.
Expert Opin Investig Drugs. 22(9), 1089-93.
(2013). The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings..
Arch Med Sci. 8(1), 6-10.
(2012). Differences in Clinical Presentation and Findings between Idiopathic Dilated and Ischaemic Cardiomyopathy in an Unselected Population of Heart Failure Patients..
Open Cardiovasc Med J. 6, 98-105.
(2012). Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?.
Curr Vasc Pharmacol. 10(3), 374-7.
(2012).